A novel adipocytokine visfatin protects against H2O2-induced myocardial apoptosis: A missing link between obesity and cardiovascular disease

Journal of Cellular Physiology

Volumn 228, Issue 3, 2013, Pages 495-501

  Xiao, Jing ^a   Sun, Bing ^a   Li, Ming ^b   Wu, Ying ^b   Sun, Xiao Bo ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLSERINE; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; HEART MUSCLE CELL; HEART PROTECTION; MITOCHONDRIAL MEMBRANE POTENTIAL; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ADIPOKINES; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, CD95; APOPTOSIS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CELL LINE; CELL SURVIVAL; CYTOKINES; HYDROGEN PEROXIDE; MYOCYTES, CARDIAC; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RATS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84870398212     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24257     Document Type: Article

References (32)

1. Benedict C, Shostak A, Lange T, Brooks SJ, Schioth HB, Schultes B, Born J, Oster H, Hallschmid M. 2012. Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): Impact of sleep loss and relation to glucose metabolism. J Clin Endocrinol Metab 97:E218-E222.
2. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. 2005. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911-2916.
3. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. 2006. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91:295-299.
4. Circu ML, Aw TY. 2010. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48:749-762.
5. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, Kosiborod M, Portnay EL, Sokol SI, Bader F, Krumholz HM. 2005. The obesity paradox: Body mass index and outcomes in patients with heart failure. Arch Intern Med 165:55-61.
6. Danial NN, Korsmeyer SJ. 2004. Cell death: Critical control points. Cell 116:205-219.
7. Davenport DL, Xenos ES, Hosokawa P, Radford J, Henderson WG, Endean ED. 2009. The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality. J Vasc Surg 49:140-147, 147 e141; discussion 147.
8. 2-induced apoptosis. FEBS J 275:3136-3144.
9. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. 2007. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 30:323-326.
10. Froy O. 2010. Metabolism and circadian rhythms-Implications for obesity. Endocr Rev 31:1-24.
11. Fujita T, Ishikawa Y. 2011. Apoptosis in heart failure. The role of the beta-adrenergic receptor-mediated signaling pathway and p53-mediated signaling pathway in the apoptosis of cardiomyocytes. Circ J 75:1811-1818.
12. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. 2005. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430.
13. Habbu A, Lakkis NM, Dokainish H. 2006. The obesity paradox: Fact or fiction? Am J Cardiol 98:944-948.
14. Khan JA, Tao X, Tong L. 2006. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13:582-588.
15. Lavrik I, Golks A, Krammer PH. 2005. Death receptor signaling. J Cell Sci 118:265-267.
16. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. 2008. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 12:1395-1403.
17. Matsuzawa Y. 2006. Therapy Insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3:35-42.
18. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. 2007. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178:1748-1758.
19. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. 2006. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 26:968-976.
20. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. 2002. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32:3225-3234.
21. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. 1994. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431-1437.
22. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. 2005. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 28:2508-2513.
23. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. 2005. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11:1096-1103.
24. Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. 2007. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 102:518-528.
25. Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. 2006. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 149:5-13.
26. Sun B, Sun GB, Xiao J, Chen RC, Wang X, Wu Y, Cao L, Yang ZH, Sun XB. 2012. Isorhamnetin inhibits HO-induced activation of the intrinsic apoptotic pathway in H9c2 cardiomyocytes through scavenging reactive oxygen species and ERK inactivation. J Cell Biochem 113:473-485.
27. von Harsdorf R, Li PF, Dietz R. 1999. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 99:2934-2941.
28. Xiao J, Sun B, Cai GP. 2010. Transient expression of interferon-inducible p204 in the early stage is required for adipogenesis in 3T3-L1 cells. Endocrinology 151:3141-3153.
29. Xiao J, Sun GB, Sun B, Wu Y, He L, Wang X, Chen RC, Cao L, Ren XY, Sun XB. 2012. Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. Toxicology 292:53-62.
30. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. 2008. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 37:663-684, ix.
31. Zeller M, Steg PG, Ravisy J, Laurent Y, Janin-Manificat L, L'Huillier I, Beer JC, Oudot A, Rioufol G, Makki H, Farnier M, Rochette L, Verges B, Cottin Y. 2005. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 165:1192-1198.
32. Zhao ZQ. 2004. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol 4:159-165.